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Treatment with Selective Serotonin Reuptake Inhibitors 
and Mirtapazine Results in Differential Brain Activation 
by Visual Erotic Stimuli in Patients 
with Major Depressive Disorder 
 
     
 
ObjectiveaaThe objective of this study was to identify patterns of brain activation elicited by 
erotic visual stimuli in patients treated with either Selective Serotonin Reuptake Inhibitors 
(SSRIs) or mirtazipine. 
MethodsaaNine middle-aged men with major depressive disorder treated with an SSRI and 
ten middle-aged men with major depressive disorder treated with mirtazapine completed the 
trial. Ten subjects with no psychiatric illness were included as a control group. We conducted 
functional brain magnetic resonance imaging (fMRI) while a film alternatively played erotic 
and non-erotic contents for 14 minutes and 9 seconds. 
ResultsaaThe control group showed activation in the occipitotemporal area, anterior cingu-
late gyrus, insula, orbitofrontal cortex, and caudate nucleus. For subjects treated with SSRIs, 
the intensity of activity in these regions was much lower compared to the control group. 
Intensity of activation in the group treated with mirtazapine was less than the control group 
but grea-ter than those treated with SSRIs. Using subtraction analysis, the SSRI group sh-
owed significantly lower activation than the mirtazapine group in the anterior cingulate 
gyrus and the caudate nucleus. 
ConclusionaaOur study suggests that the different rates of sexual side effects between the 
patients in the SSRI-treated group and the mirtazapine-treated group may be due to dif-
ferent effects on brain activation. 
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Introduction 
 
Our understanding of the brain substrates for sexual response is accumulating due
to the development of functional imaging techniques such as positron emission tomo-
graphy (PET) and functional magnetic resonance imaging (fMRI).
1,2 Park et al.
3 in-
vestigated relationships between brain activation and sexual response in 12 young ma-
les (mean age=23 years) with normal sexual function. They reported that the brain 
areas activated by erotic visual stimuli were the inferior frontal lobe, cingulate gyrus,
insula, corpus callosum, caudate nucleus, globus pallidus, inferior temporal lobe, and
thalamus. Arnow et al.
2 developed an experimental paradigm to evaluate regional brain
activation during sexual arousal that included an objective measure of penile tume-
scence and erotic visual stimuli, as well as presentation of neutral and visually stimulat-
ing control segments using fMRI technology. The major areas of activation associated
with tumescence were the right insula/subinsular region, including the claustrum, cau-
date nucleus, putamen, cingulate gyrus, occipito-temporal area, and hypothalamus. A
study comparing gender differences in sexual stimuli showed that only male subjects 
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exhibited significant activation of hypothalamus.
4 
The impairment of sexual function in patients with depre-
ssion is very common. One-third to one-half of patients 
with untreated depression have sexual difficulties manife-
sted by decreased interest, and/or libido, erectile dysfunc-
tion or delayed ejaculation. Additionally, most antidepre-
ssants also create or increase sexual dysfunction. These 
side effects and sexual dysfunction increase with age. 
Mirtazapine is a noradrenergic and a specific seroto-
nergic antidepressant with a mode of action that is dis-
tinguished from popularly available antidepressants such 
as selective serotonin reuptake inhibitors (SSRIs). This 
drug is an antagonist of α2 receptors, and facilitates rel-
ease of norepinephrine and serotonin.
5 The enhancement 
of serotonergic neurotransmission is specifically mediat-
ed via 5-hydroxytryptamine (5HT)-1 receptors since mir-
tazapine is a postsynaptic serotonergic 5HT2 and 5HT3 
antagonist.
6 Data from clinical trials have shown that mir-
tazapine has an overall clinical efficacy similar to that of 
tricyclic antidepressants and has a relative absence of cho-
linergic, adrenergic, and serotonergic side effects.
7-9 A se-
ries of studies suggest that the patients who have trouble-
some sexual side effects with SSRIs can show continued 
remission of depression as well as a return to satisfactory 
sexual functioning when switching to or augmenting with 
mirtazapine.
10-12 
Sexual dysfunction is one of the most common com-
plaints amongst depressed patients. Not only depression 
itself but also other psychiatric illnesses or general med-
ical conditions can cause sexual difficulties manifested 
by decreased interest, and/or libido, erectile dysfunction 
or delayed ejaculation. Additionally, most antidepressants 
induce or increase sexual dysfunction. While these side 
effects and sexual dysfunction increase with age,
13 the 
SSRIs, venlafaxine, the tricyclic antidepressants, and mo-
noamine oxidase inhibitors (MAOIs) are all associated with 
a decrease in sexual desire, impotence, delayed ejaculation, 
and anorgasmia. These drugs also can affect all phases of 
sexual activity: desire, arousal, orgasm, and ejaculation. 
However, several studies have demonstrated that the most 
widely-used antidepressants, SSRIs, are especially associ-
ated with higher rates of sexual dysfunction.
14 
Compared with SSRI, mirtazapine is reported to be 
less associated with sexual dysfunction. Although 5HT2 
and 5HT3 antagonism are thought to underlie the decre-
ase in sexual dysfunction, the precise mechanism is not 
yet clear. Nowadays, neuroimaging studies about the neu-
ral correlates with sexual function are gaining attenti-
on
15,16 and pharmacoMRI may reveal differential brain 
activation between these two classes of antidepressants. 
We carried out this study in order to observe whether 
there are differences in brain activation elicited by visual 
erotic stimuli in elderly patients with depression treated 
with SSRIs or mirtazapine, and to identify the different 
regions that are associated with sexual dysfunction. 
 
Methods 
 
Subjects and assessments 
Twenty-three depressed patients currently on SSRI or 
mirtazapine treatment and twelve healthy controls parti-
cipated in the study. The participants were all age-match-
ed and had no prior psychiatric illness. All participants 
were heterosexual, right-handed middle-aged males from 
40 to 60 years of age. In the control group, we excluded 
those who had a history of sexual arousal disorder or erecti-
le dysfunction, and those with medical illness or history such 
as diabetes mellitus, hypertension, or other serious illness. 
The subjects in the depression group were diagnosed 
with major depressive disorder by two board-certified psy-
chiatrists according to the Diagnostic and Statistical Ma-
nual of Mental Disorders (DSM)-IV criteria. The Struc-
tured Clinical Interview, DSM-IV Axis I Disorders-Cli-
nician Version,
17 was assigned to all patients and controls. 
Those with medical illness or history such as diabetes mel-
litus, hypertension, or other serious illness were excluded. 
The symptom score in the 17-Item Hamilton Rating 
Scale for Depression (HAM-D)18 and in the Clinical Glo-
bal Impression-Severity of Illness (CGI-S)19 scale score 
was obtained for each subject in the depression group. 
Adverse side-effects of drug treatment were obtained at 
the time of enrollment. The absence of physical disorders 
and of any pharmacological treatment other than the an-
tidepressants was checked through a medical examina-
tion. 
All potential subjects were screened via a one-hour 
interview and were encouraged to fill out various ques-
tionnaires including the Brief Male Sexual Function 
Inventory (BSFI)20. The BFSI is a validated self-report 
measure on sexual functioning. The Inventory covers sex-
ual drive and satisfaction, erectile function, ejaculatory 
function, as well as the problem assessment of drive, er-
ection, and ejaculation. The item scaling ranges from 0 
(no function, big problem, etc.) to 4 (good function, no 
problem, etc.) while the domain score is calculated by 
adding the item scores. Lower scores mean poorer function. 
Eight patients in the SSRI group were taking paroxetine 
while four were taking fluoxetine. There were eleven 
patients in the mirtazapine group. The mean duration of 
depressive illness was 32±17.8 weeks in the SSRI group, 
and 36±14.9 weeks in the mirtazapine group. The mean 
duration of medication for the SSRI group was 11±4.9 
weeks, and 10±5.4 weeks in the mirtazapine group. The 
duration of illness and the duration of medication betw- 
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een the two antidepressant groups were not different. 
The selected subjects were thoroughly briefed on the 
design of the study, allowed to read and sign a written 
consent form before participating. The study protocol was 
approved by the institutional review board at St. Mary’s 
Hospital, The Catholic University of Korea. 
 
Activation stimuli and MRI image acquisition 
We presented a film clip that lasted for 14 minutes and 
9 seconds to each subject. Each clip consisted of alterna-
ting segments of relaxing scenes (R), sports highlights 
(S), and sexually arousing erotic scenes (E) in the follow-
ing order: S, R, E, R, E, R, S, R, S, R and E. The 
respective times for each segment in seconds were: 129, 
60, 120, 30, 120, 30, 120, 30, 60, 30, 120 (seconds). The 
contents from the relaxing scenes were natural scenes 
such as the mountains and the valleys while the scenes 
from the sports highlights were various scenes from two-
person competitions in the Olympic Games. There was 
one factor that had to be taken into consideration: Given 
data suggesting that subjects disengaged from emotionally 
stimulating visual material under fMRI conditions for a 
period of approximately 15 seconds, the S and E seg-
ments were not contiguous and were separated by a mi-
nimum of 30 s of R.
21 The content of the erotic segme-
nts involved four types of sexual activities: rear-entry 
intercourse, intercourse with the female in the superior 
position, fellatio and sexual intercourse with the male in 
the superior position. Of the eight different segments de-
picting sexual activity, these four activities were associat-
ed with the highest level of perceived sexual arousal and 
penile erection in a sample of 40 healthy males. Additio-
nally, in order to control for a possible anticipation effect, 
subjects were not aware of the ordering of the segments. 
During the fMRI sessions, the film clips were presented 
to the subjects through a mirror located at the top of the 
head coil that receives video-images from outside of the 
magnetic room. Echoplanar images (EPI) were acquired 
on a 1.5 Tesla MRI system (Magnetom Vision Plus, Sie-
mens, Erlangen, Germany). Thirty slices (5 mm thick) 
were acquired every 3.106 seconds in an inclined axial 
plane, aligned with the AC-PC axis. These T2-weighted 
functional images were acquired using an EPI pulse seq-
uence (TR=0.6 msec, TE=60 msec, Flip 90, FOV=240 mm, 
Matrix=64×64). After functional scanning, high-resolu-
tion data were acquired via a T1-weighted 3D volume ac-
quisition obtained using a gradient echo pulse sequence 
(TR=9.7 msec, TE=4 msec, Flip=12, FOV=240 mm, Ma-
trix=200×256). 
Data were analyzed using Statistical Parametric Map-
ping (SPM99, Wellcome Department of Cognitive Neu-
rology, London, UK). Scans were realigned and spatially 
normalized using the standard Montreal Neurological In-
stitute (MNI) template. Images were then convolved in 
space with a 3D isotopic Gaussian kernel (full width at 
half maximum, FWHM, of 8 mm) to improve the signal-
to-noise ratio and to accommodate residual variations in 
functional neuroanatomy that usually persist between sub-
jects after spatial normalization. Effects at each and ev-
ery voxel were estimated using the general linear model. 
Voxel values for each contrast yielded a statistical para-
metric map of the t statistic (SPMt) and subsequently tr-
ansformed to the unit normal distribution, SPM {Z}. A 
“random-effects model” was implemented to produce the 
E (erotica) minus N (neutral) contrasts. This model was 
implemented within SPM99 using a multi-stage approach. 
The hypothalamus, thalamus, anterior cingulate gyrus, 
occipitotemporal cortex, anterior temporal cortex, parietal 
cortex, amygdala, hippocampal formation, orbitofrontal 
cortex, ventral striatum, the claustrum, the nucleus accum-
bens, and the parietal lobules have been reported to show 
increased activation in response to sexually explicit films 
in male subjects.
2-4,22 For each of the brain areas mention-
ed above, a set of coordinates was calculated by taking 
the average for each orthogonal axis X, Y and Z of report-
ed Talairach coordinates.
23 Predetermined regions of in-
terest (ROI) were limited by spheres having a radius of 9 
mm and for center, the calculated average reported coor-
dinates. For these a priori ROIs, the height threshold was 
set at p<0.001 (z=3.09), uncorrected for multiple com-
parisons. For other brain areas, the height threshold was 
set at p<0.05, corrected for multiple comparisons. 
 
Results 
 
Of the twelve subjects initially enrolled in the control 
group, ten subjects finished the fMRI study with reliable 
imaging data. One subject withdrew his consent and drop-
ped out of the study as he experienced discomfort while 
in the MRI gantry during the scan. The other subject’s 
head movement was out of the permitted range and the 
data were unreliable. The results from the remaining nor-
mal middle-aged subjects have been previously described.
24 
Of the subjects initially enrolled in the experimental 
groups, three subjects violated the study protocol (taking 
other antidepressants and sildenafil) between the periods 
of enrollment and fMRI scan. Because one subject’s scan 
had marked noise due to technical reasons, the data were 
excluded from further analysis. We thus analyzed data for 
nine subjects undergoing treatment with SSRIs (6 parox-
etine, 3 fluoxetine) and ten patients undergoing treat-
ment with mirtazapine. There were no statistically signi-
ficant differences between the two groups in baseline 
demographics and clinical data (Table 1). The daily mean  
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dosages throughout the present study were 33.9 mg/day 
for the SSRI group and 39.8±10.0 mg/day for the mirta-
zapine group. None of the patients reported serious ad-
verse events and were able to generally tolerate both 
treatments well. There were significant differences in 
the scores on the Brief Male Sexual Function Inventory 
(BSFI)20 between the control subjects and the depres-
sive patient group treated with antidepressants. There was 
no significant differences in the BSFI scores between the 
SSRI treated group and the mirtazapine treated group. 
When the blood oxygen level dependent (BOLD) ac-
tivity while viewing emotionally neutral film segments (S) 
in the control group was subtracted from that obtained 
while viewing erotic segments (E), there was a significant 
(p<0001, uncorrected) pattern of activation that repre-
sented brain regions that responded to the visual sexual 
stimuli in the control group, the SSRI group, and the mir-
tazapine group (Figure 1A, B and C). As shown in pre-
vious reports,
24 healthy middle-aged male controls show-
ed activation in the occipitotemporal area, anterior cingu-
late gyrus, insula, orbitofrontal cortex and caudate nucle-
us after viewing visual sexual stimuli (Figure 1A). Mean-
TABLE 1. Demographic and clinical characteristics of normal con-
trol subjects, depressive patients treated with selective serotonin
reuptake inhibitors (SSRI) and mirtazapine (mean±SD) 
Characteristics 
Control 
(N=10) 
SSRI-treated 
depression 
(N=9) 
Mitrazapine-treated 
depression 
(N=10) 
Age (years) 51.9±2.7 51.6±2.7 51.4±2.7 
HAMD*  06.4±2.0 24.4±4.4 24.9±4.7 
CGI-S*  01.4±0.5  04.3±0.5  04.4±0.5 
BSFI* 30.8±2.7 13.7±4.5 16.5±5.4 
*p<0.001, Kruskal-Wallis Test [Posthoc test by Man-Whitney U test;
HAMD- Control <SSRI group, mirtazapine group (p<0.001); CGI-S-
Control <SSRI group, mirtazapine group (p<0.001), BSFI- Control 
>SSRI group, mirtazapine group (p<0.001)]. HAM-D: Hamilton Ra-
ting Scale for Anxiety, CGI-S: Clinical Global Impression-Severity 
of Illness, BSFI: Brief Male Sexual Function Inventory 
 
FIGURE 1. A: Axial view of activated brain areas by erotic visual stimuli in healthy controls.
A 
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while, depressed patients treated with SSRI showed lo-
wer BOLD activity patterns than in the control group (Fig-
ure 1B). The brain activation elicited by sexual images 
in the depressed patients treated with mirtazapine also 
showed lower activation compared to that of the control 
group although less decreased than in the SSRI group 
(Figure 1C). 
These patterns were more definitive when the BOLD 
activity elicited by the erotic visual stimuli in the SSRI 
group and the mirtazapine group was subtracted from 
that obtained from the control group. There were signifi-
cant (p<0.05, corrected for multiple comparisons) differ-
ences in several brain regions activated in response to sexual 
visual stimuli between the control group and the patients 
treated with antidepressants. Superior frontal gyrus, post-
central gyrus and pons seemed to be less activated than 
in the controls amongst the patients in the SSRI group 
(Table 2, Figure 2A). For the patients in the mirtazapine 
group, right thalamus is activated significantly less than 
those in the control group (Table 3, Figure 2B). Additio-
nally, when the BOLD activity for the SSRI group was 
subtracted from that of the mirtazapine group, the erotic 
image-elicited BOLD activity from the SSRI group showed 
significantly lower activation in the anterior cingulate gy-
rus and the caudate nucleus than that of the mirtazapine 
group (Table 4, Figure 2C). 
 
Discussion 
 
Sexual dysfunction is one of the most frequent and dis-
FIGURE 1. Continued. B: Axial view of activated brain areas by erotic visual stimuli in patients with depression who treated with SSRI. SSRI:
selective serotonin reuptake inhibitor. 
B 
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tressing side effects in treatment with common antidepre-
ssants such as SSRIs and serotonin norepinephrine reup-
take inhibitors (SNRIs).
25 These effects are associated 
with increased serotonergic tone and various serotonin 
receptors such as 5HT1a and 5HT2 receptors.
6 A recent 
attempt to specify the detailed sexual inhibitory effects 
of serotonin showed that there is an inhibitory role of 
serotonin in the lateral hypothalamic area.
26 This is con-
sistent with the well-established inhibitory effects of SSRIs 
on sexual response.
27 However the precise physiologic 
mechanisms that mediate this phenomenon are as yet un-
known. 
Our results showed that cortical areas such as right 
postcentral gyrus, left superior frontal gyrus and pons ac-
tivated significantly less in depressed patients treated with 
SSRIs compared to the normal middle-aged healthy male 
subjects. As reported previously, the middle-aged healthy 
subjects showed less hypothalamic and thalamic activa-
tion compared to the younger men.
24 Yang
28 also examined 
brain activation from visual sexual stimuli amongst the 
depressed patients with sexual dysfunction and reported 
TABLE 2. Differences of activated brain regions in response to
sexually explicit and emotionally neutral visual stimuli between nor-
mal healthy control subjects and patients with depression who tr-
eated with SSRI (substraction: normal healthy control minus pati-
ents with depression who treated with SSRI) 
Z-score x,  y,  z  (mm) Regions 
2.84  -36  -30  -62  Right postcentral gyrus 
2.59 -26    -02  -66  Left superior frontal gyrus 
2.56  -28  -40  -66  Right postcentral gyrus, (BA 5) 
2.46  -18  -30  -24  Right pons 
SSRI: selective serotonin reuptake inhibitor, BA: Brodmann’s Area
 
FIGURE 1. Continued. C: Axial view of activated brain areas by erotic visual stimuli in patients with depression who treated with mirtazapine.
C 
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that hypothalamus as well as thalamus were both less ac-
tivated than the normal control subjects. Therefore, we can 
suggest that the middle-aged depressive patients under-
going SSRI treatment suffer more sexual dysfunction due 
to less hypothalamic and thalamic activation as well as a 
decrease in cortical activation. However, since hypome-
tabolism of the left prefrontal area was also reported 
amongst depressive patients,
29 it is difficult to clarify whe-
ther hypoactivation of left superior frontal gyrus is due 
to the SSRI or the depression itself. 
In our results, the BOLD activities in the patients with 
mirtazapine showed greater intensity than the SSRI group, 
among cingulate gyrus, right frontotemporal lobe, and left 
caudate head. These results suggest that patients taking 
SSRIs may have more difficulties in normal sexual func-
tioning compared to patients taking mirtazapine since 
the cingulate gyrus and caudate nucleous are known to 
be important neuroanatomical regions for normal sexual 
function. Human sexual arousal is proposed to be a multi-
dimensional experience comprised of four closely interre-
lated and coordinate components: cognitive, emotional, 
TABLE 3. Differences of activated brain regions in response to sex-
ually explicit and emotionally neutral visual stimuli between normal
healthy control subjects and patients with depression who treated
with mirtazapine (substraction: normal healthy control minus pati-
ents with depression who treated with mirtazapine) 
Z score  x, y, z (mm) Regions 
2.04  16  -24  6  Right thalamus, pulvinar 
 
FIGURE 2. A: Differences of activated brain regions in response to sexually explicit stimuli between control and patients with SSRI treated 
depression (substraction images: normal healthy control minus patients with depression who treated with SSRI). SSRI: selective serotonin 
reuptake inhibitor. 
A 
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motivational, and physiological, that are all mediated by 
the brain.
22,30 While caudate nucleus is reported to be cor-
related with the urge to perform hand-washing rituals in 
patients with obsessive-compulsive disorder, McGuire et 
al.
31 noted that during viewing of an erotic film, subjects 
were simultaneously confronted with the urge to act and 
with the impossibility to do so, hence suggesting a role 
for the ventral striatum in the control of the motor expres-
sion of sexual arousal, that is, in withholding the motor 
output of sexual arousal. Such a role could be implement-
ed through the anatomic projections that the striatum 
receives from the cognitive subdivision of the anterior 
cingulate cortex.
32 Reiman et al.
33 also provided some 
evidence that the anterior cingulate gyrus is involved in 
the conscious experience of emotion. In a functional neu-
roimaging study, the activation of the anterior cingulate 
gyrus was highly correlated with the levels of perceived 
sexual arousal associated with the perceived urge to per-
form sexual actions.
22 The anterior cingulate is subdivided 
TABLE 4. Differences of activated brain regions in response to sex-
ually explicit and emotionally neutral visual stimuli between patie-
nts with depression who treated with mirtazpine and who treated
with SSRI (substraction: patients with depression who treated with
mirtazapine minus patients with depression who treated with SSRI)
Z-scores x,y,z  (mm) Regions 
2.52  0-2  0-8  -36 Left  cingulate  gyrus  (BA 24) 
2.37  -60  -12  -00 Right  frontotemporal  lobe 
2.35 -12    -20  0-2 Left  caudate  head 
2.34  -02  -06  -32 Right  cingulate  gyrus 
SSRI: selective serotonin reuptake inhibitor 
 
FIGURE 2. Continued. B: Differences of activated brain regions in response to sexually explicit stimuli between normal healthy control and
patients with mirtazapine treated depression (substraction images: normal healthy control minus patients with depression who treated with
mirtazapine). 
B 
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into “affect” and “cognition” components, assessing the 
motivational content of the internal and external stimuli 
and regulating context-dependent behaviors often engaged 
in responses associated with affect.
32 According to this 
neurobehavioral view, the activation of the anterior cin-
gulate cortex may reflect the maintenance of the corres-
pondence between the sexual response and the affective 
value of the stimulus. Ferretti et al.
16 also suggested that 
anterior cingulate had a major role in the every phase of 
male sexual arousal, while other brain region such as in-
sula and hypothalamus are more activated in some phases. 
Activity in the anterior cingulate was also associated with 
sexual arousal of women in some studies.
34,35 These re-
sults have been replicated in several studies using fMRI 
amongst healthy young subjects.
2-4,16 Therefore, it sug-
gests that the differential activation of cingulate gyrus 
and caudate nucleus obtained in this study reflects the 
different sexual dysfunctional effects of mirtazapine and 
SSRI. 
We have found that fMRI during the presentation of 
sexually arousing stimuli in patients undergoing antide-
pressant therapy is useful for gaining a better understand-
ing of the exact nature of the brain’s response during the 
time of sexual arousal. It would also provide a potential 
means to objectively measure brain activation in response 
to sexually arousing stimuli. 
Finally, the present study supported the notion that the 
different rates of incidence in sexual dysfunction amongst 
FIGURE 2. Continued. C: Differences of activated brain regions in response to sexually explicit stimuli between patients with mirtazapine
treated depression and SSRI treated depression (substraction images: patients with depression who treated with mirtazapine minus pa-
tients with depression who treated with SSRI). SSRI: selective serotonin reuptake inhibitor. 
C 
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the patients treated with SSRIs and mirtazapine could re-
flect their different mechanisms of action in the brain. By 
and large, SSRI treatment results in more profound dys-
functional effects on the sexual activities within brain than 
does mirtazapine treatment. Thus our results support that 
mirtazapine is superior to SSRIs in the aspect of sexual 
side effect profiles. 
An important issue is the general effect of antidepres-
sant on blood flow. In fMRI, activations measured are an 
indirect reflection of neural activity but a direct reflection 
of the difference between the magnetic properties of oxy-
genated and deoxygenated hemoglobin or BOLD respon-
se. Theoretically, it is possible that serotonin influenced 
blood flow or BOLD changes in the present study. SSRIs 
and mirtazapine may decrease the activation of BOLD 
through serotonergic and histaminergic affinities, but this 
is a controversial point. SSRIs have been regarded as 
good tools to use in pharmacoMRI studies to manipulate 
the serotonergic system.
36 SSRIs and mirtazapine in ge-
neral have few cerebrovascular effects.
37,38 Therefore, it 
is unlikely that general effects on the BOLD response 
caused by SSRIs and mirtazapine influenced the results. 
There are several limitations of this study. First, a rela-
tively small number of heterogeneous subjects participated 
in the study. We included patients taking either fluoxetine 
or paroxetine as the SSRI group although the two antide-
pressants are somewhat different pharmalogically. Second, 
we did not apply objective measures of sexual arousal 
such as penile tumescence. We assessed sexual function 
using only the BSFI questionnaire. In addition, we did 
not perform the BSFI questionnaire before starting the 
antidepressant treatment. Third, we did not include audi-
tory stimuli in this paradigm. Although sound is important 
in sexual activation, we showed only visual stimuli for 
the simple paradigm. Fourth, the activated regions in the 
comparison between patients and controls could be due 
to depressive symptoms as well as the effect of medica-
tion at the same time. Therefore we cannot make clear 
that the different activation is due to medication. The 
different thresholds for a priori and other brain areas in-
cluded in the analysis could skew the results. Because 
depression also causes sexual dysfunction, the lack of 
assessment excluding the effect of antidepressant is one 
of its limitations. However, we recruited the subjects who 
stated that their sexual dysfunction develops after taking 
the antidepressant. Additionally, we did not measure bra-
in activity occurring before starting the treatment with 
the antidepressant. Nevertheless, we did find the diffe-
rence in BOLD activities between the mirtazapine group 
and the SSRI group. The result may reflect the difference 
in sexual dysfunction profile between the two antidepres-
sants. The regions that showed the differences in BOLD 
activities were similar to that of the brain regions known 
to be related with normal sexual function. Finally, altho-
ugh we did not find a direct correlation between the re-
ported sexual dysfunction and the brain activations by 
fMRI study, our study was meaningful because it was the 
first attempt to directly compare the effect of SSRIs and 
mirtazapine on patterns of brain activation. As neurosci-
ence has progressed, the relation between the patterns of 
brain activation and clinically relevant features has ga-
thered much interest. Research such as this preliminary 
study will assist the exploration of the labyrinth of various 
psychiatric clinical problems. 
We found differences in patterns of brain activation 
between SSRI treated- and the mirtazapine-treated groups 
after depressive patients viewed erotic visual stimuli. Our 
results showed that BOLD activity was less intense in 
the SSRI treated group than in the control group. The cin-
gulate gyrus, right frontotemporal lobe, and left caudate 
head activated significantly more in response to erotic 
visual stimuli in the mirtazpine group than the SSRI g-
roup. Therefore, our study suggests that different rates of 
sexual adverse events amongst the patients in the SSRI-
treated group and the mirtazapine-treated group may be 
due to differential effects of these drugs in the brain. 
Furthermore, the results indicate the neural substrates un-
derlying the relatively less profound sexual dysfunction 
experienced by patients on mirtazapine as opposed to SSRIs. 
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